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Radiotherapy plays a central part in cancer treatment,  and use of radiosensitizing agents can greatly 
enhance this modality.  Although studies have shown that several chemotherapeutic agents have the 
potential to increase the radiosensitivity of tumor cells,  investigators have also studied a number of 
molecularly targeted agents as radiosensitizers in clinical trials based on reasonably promising pre-
clinical data.  Recent intense research into the DNA damage-signaling pathway revealed that ataxia-
telangiectasia mutated (ATM) and the Mre11-Rad50-NBS1 (MRN) complex play central roles in DNA 
repair and cell cycle checkpoints and that these molecules are promising targets for radiosensitization.  
Researchers recently developed three ATM inhibitors (KU-55933,  CGK733,  and CP466722) and an MRN 
complex inhibitor (mirin) and showed that they have great potential as radiosensitizers of tumors in 
preclinical studies.  Additionally,  we showed that a telomerase-dependent oncolytic adenovirus that we 
developed (OBP-301 [telomelysin]) produces profound radiosensitizing eﬀects by inhibiting the MRN 
complex via the adenoviral E1B55kDa protein.  A recent Phase I trial in the United States determined 
that telomelysin was safe and well tolerated in humans,  and this agent is about to be tested in combi-
nation with radiotherapy in a clinical trial based on intriguing preclinical data demonstrating that 
telomelysin and ionizing radiation can potentiate each other.  In this review,  we highlight the great 
potential of ATM and MRN complex inhibitors,  including telomelysin,  as radiosensitizing agents.
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adiotherapy is one of the standard treatment 
options for various malignant cancers and is 
often combined with surgical resection and/or chemo-
therapy as a part of multidisciplinary treatment.  More 
than 50ｵ of patients with cancer receive radiother-
apy at some point during their treatment process [1].  
Like surgical resection,  radiotherapy is a local treat-
ment,  and it often targets not only primary tumors but 
also regional lymph nodes.  One of the advantages of 
radiotherapy over surgical resection is that it is less 
invasive; for that reason,  radiotherapy contributes 
signiﬁcantly to treatment of cancers in areas of the 
body in which resection could greatly impair quality of 
life,  such as the esophagus and the head and neck.  
Although the systemic side eﬀects of radiotherapy are 
much less severe than those of chemotherapy,  radio-
therapy sometimes causes severe local adverse eﬀects 
such as radiodermatitis,  because normal tissues adja-
cent to tumors are usually included in the radiation 
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ﬁelds.  Although both stereotactic and fractionated 
radiotherapy have contributed to the improvement of 
irradiation methods in clinical practice,  radiotherapy 
still has plenty of room for improvement [2,  3].
　 Hypoxia is one of the major limitations of radio-
therapy,  and researchers have made many attempts to 
improve it,  such as through oxygenation,  blood trans-
fusion,  and treatment with erythropoietin [4-6].  
Although the oxygen level in a tumor is one of the 
most important factors in its response to radiother-
apy,  improving the local tumor control and survival 
rates for radiotherapy using pretreatment oxygenation 
is controversial.  In one study,  correction of tumor 
hypoxia signiﬁcantly improved the locoregional tumor 
control and overall survival rates after radiotherapy 
for head and neck cancer,  but was less eﬀective for 
other types of cancer [7].  Although the rationale for 
intratumoral oxygenation before radiotherapy appears 
to be convincing,  oxygenation alone does not improve 
radiotherapy suﬃciently.
　 Many studies have been conducted in an attempt to 
improve radiotherapy,  with much of the work being 
based on either of 2 hypotheses (Fig.  1).  The ﬁrst is 
that radiosensitizing agents should increase the cyto-
toxic eﬀects of radiation on cancer cells by increasing 
the cellsʼ radiosensitivity.  The second is that radio-
protective agents should decrease the adverse eﬀects 
of radiation on normal cells by increasing their 
radioresistance.  In this review,  we describe several 
chemotherapeutic and molecularly targeted agents that 
have displayed radiosensitizing eﬀects in preclinical 
and/or clinical studies and then focus on the potential 
of inhibitors of ataxia-telangiectasia (A-T) mutated 
(ATM) and the Mre11-Rad50-Nijmegen breakage syn-
drome (NBS) 1 (MRN) complex as radiosensitizing 
agents.  Furthermore,  we highlight the great potential 
of OBP-301 (telomelysin),  a telomerase-dependent 
oncolytic adenovirus that we developed,  as an MRN 
complex inhibitor.
DNA Double-Strand Break Response: DNA 
Repair and Cell Cycle Checkpoints
　 Following DNA double strand-breaks (DSBs) 
induced by ionizing radiation,  DNA repair and cell 
cycle checkpoints are the main mechanisms of mainte-
nance of genomic stability [8].  Cells have several 
checkpoints that function at various phases of the cell 
cycle.  Speciﬁcally,  the G1/S and intra-S checkpoints 
prevent inappropriate DNA replication,  whereas the 
G2/M checkpoint prevents cells with DNA damage 
from entering mitosis.  When these checkpoints detect 
DNA damage at each phase,  they induce cell cycle 
arrest and make time for repair of DNA damage.  
ATM plays a central role in the DNA damage 
response pathway by controlling the checkpoints via 
eﬀector proteins such as Chk1,  Chk2,  p53 and 
BRCA1.
　 Homologous recombination (HR) and nonhomolo-
gous end joining (NHEJ) are major DNA DSB repair 
pathways,  and cells use them according to the phase 
of the cell cycle and condition of the DSB ends [9,  
10].  HR provides accurate genetic recombination 
using a sister chromatid as a template,  which is 
essential for maintenance of genomic stability.  
Although HR is a desirable method of DNA DSB 
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Fig. 1　 Approaches to improvement of radiotherapy.  Radiosen-
sitizing agents are designed to increase the cytotoxic eﬀects of 
radiation on cancer cells,  and radioprotective agents are designed 
to decrease the adverse eﬀects of radiation on normal cells.  Hsp90,  
heat shock protein 90; NF-κB,  nuclear factor-κB; COX-2,  
cyclooxygenase-2.
repair,  it is limited in cells during the S and G2 
phases because of the need for a sister chromatid.  
NHEJ is a simple method of directly connecting the 
DSB ends.  Although NHEJ is not as accurate as HR,  
it plays an important role in minimizing DNA damage,  
especially in cells in the G0 and G1 phases,  in which 
HR is not available.  Ku70/80,  the DNA-dependent 
protein kinase,  catalytic subunit,  and DNA ligase IV 
are major contributors to NHEJ.
　 DNA repair and cell cycle checkpoints must coop-
erate closely to repair DNA damage and maintain 
genomic stability.  Defects in this network produce 
dysfunction in the repair of DNA damage induced by 
ionizing radiation,  which results in enhancement of the 
cytotoxic activity of radiation.  Thus,  molecules 
involved in these mechanisms can be suitable targets 
for radiosensitization.
Chemotherapeutic Agents as Radiosensitizers
　 As described above,  radiotherapy is often com-
bined with chemotherapy,  and several chemotherapeu-
tic agents are known to enhance the radiosensitivity of 
cancer cells [11,  12].  5-Fluorouracil (5-FU),  one of 
the most commonly used chemotherapeutic agents,  is 
a member of the thymidylate synthase inhibitor family;  
these inhibitors produce cytotoxic eﬀects by interfer-
ing with DNA synthesis [13].  Researchers have tested 
the combination of 5-FU and ionizing radiation and 
shown it to be eﬀective against various types of can-
cers.  This combination is a central component of 
current chemoradiation regimens [14].
　 Cisplatin,  another commonly used chemotherapeu-
tic agent,  causes cytotoxicity by cross-linking DNA 
and interfering with cell division.  Although cisplatin 
use is often combined with radiotherapy,  oxaliplatin,  
another platinum derivative,  has displayed more pro-
found radiosensitizing eﬀects [14,  15].
　 Gemcitabine,  which is a nucleoside analogue that 
produces cytotoxic activity by blocking DNA replica-
tion,  is another chemotherapeutic agent that is consid-
ered to be a radiosensitizer [16].  In preclinical 
studies,  gemcitabine produced radiosensitization by 
interfering with Rad51 function and HR repair [17] 
as well as by redistributing cells into S phase by cor-
relating with Chk1 and Chk2 [18].  Gemcitabine and 
radiotherapy have been shown to exert synergistic 
eﬀects against cancers of the lung,  pancreas,  and 
head and neck in several clinical trials [19-21].
　 Taxanes such as paclitaxel and docetaxel produce 
cytotoxic activity by disrupting the function of micro-
tubules that lead to cell division.  A remarkable point 
is that taxanes arrest cells at the G2/M phase,  which 
is the phase at which ionizing radiation is most eﬀec-
tive [22].  Not only preclinical studies but also sev-
eral clinical trials of regimens including taxanes and 
ionizing radiation used to treat cancers of the head and 
neck,  esophagus,  and lung have shown that taxanes are 
eﬀective radiosensitizers [23-27].
　 Topoisomerase I inhibitors such as irinotecan,  
topotecan,  and camptothecin interfere with topoiso-
merases,  which are enzymes that are essential for 
winding and unwinding the DNA double helix during 
DNA replication and repair.  Considering that ionizing 
radiation targets DNA and causes DNA DSBs,  the 
combination of a topoisomerase I inhibitor and ionizing 
radiation may produce synergistic eﬀects.  Many pre-
clinical studies using cultured cells and animal models 
have supported the synergy of this combination,  
although the speciﬁc mechanism of the synergistic 
eﬀects remains unclear [28].  Also,  many clinical trials 
have shown that these combinations are eﬀective 
against various solid tumors,  including head and neck,  
esophageal,  lung,  and brain tumors [29-32].
Molecularly Targeted Therapy for 
Radiosensitization
　 Although traditional chemotherapeutic agents that 
target rapidly dividing cells are still central to current 
cancer therapy,  the attention of scientists is moving 
toward targeted therapy,  which is expected to increase 
the eﬀectiveness of treatment against cancer cells 
while reducing its harmfulness to normal cells [33].  
Several small molecules and monoclonal antibodies 
that target epidermal growth factor receptor (EGFR),  
Her2/neu receptor,  and vascular endothelial growth 
factor (VEGF) are currently in clinical use,  and 
investigators have developed various types of molecu-
larly targeted agents and are currently testing them in 
clinical trials [34,  35].  Some examples of molecu-
larly targeted agents that are undergoing testing in 
clinical trials and expected to be used as radiosensi-
tizers of tumors are described below.
　 Histone deacetylases (HDACs) are enzymes that 
control histone acetylation in coordination with the 
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opposing actions of histone acetyltransferases and play 
important roles in the regulation of gene expression.  
Physicians have long employed HDAC inhibitors such 
as valproic acid as anticonvulsants and mood-stabiliz-
ing drugs in the clinic,  and use of these agents 
recently has generated a great deal of interest in their 
potential as antitumor drugs [36].  HDAC inhibitors 
have induced tumor-selective apoptosis and growth 
arrest in preclinical studies and exhibited eﬀective-
ness against tumors alone or in combination with che-
motherapy in many clinical trials [37,  38].  To date,  
two HDAC inhibitors approved by the U.S.  Food and 
Drug Administration―vorinostat and romidepsin―
are in clinical use for treatment of T-cell lymphoma.  
Regarding the potential radiosensitizing eﬀect of 
HDAC inhibitors,  histone hyperacetylation induced by 
HDAC inhibitors appears to increase the cytotoxic 
activity of ionizing radiation [39,  40],  and several 
clinical trials are testing these inhibitors in combina-
tion with radiotherapy for many types of cancer [41,  
42].
　 Poly (ADP-ribose) polymerase (PARP) enzymes 
are proteins that play critical roles in DNA repair and 
replication.  PARP1,  which is the most abundant 
PARP and accounts for most PARP activities in 
cancer cells,  binds to both DNA single-strand breaks 
(SSBs) and DSBs,  but its role in SSB repair is bet-
ter established.  Although PARP inhibitors mainly 
contribute to SSB repair and often do not directly 
contribute to DSB repair,  which is more critical for 
cell survival,  defects in HR brought about by PARP 
inhibitors appear to increase the cytotoxic activity of 
ionizing radiation,  especially in cells that are defec-
tive in DSB repair or NHEJ function [43-46].  Many 
PARP inhibitors are currently in clinical trials as 
single agents or in combination with DNA damage-
inducing chemotherapeutic agents,  and the PARP 
inhibitor ABK-888 administered in combination with 
radiotherapy recently entered clinical trials [47].
　 In addition,  inhibitors of heat shock protein 90 or 
Chk1/2,  some of which are currently in clinical trials 
as monotherapy or in combination with chemothera-
peutic agents,  have exhibited potential as radiosensi-
tizers in preclinical studies,  although combinations of 
them with radiotherapy have yet to be tested in clini-
cal trials as far as we know [48-50].  Some EGFR 
tyrosine kinase inhibitors such as erlotinib and geﬁ-
tinib and VEGF inhibitors such as bevacizumab,  
which are currently in clinical use for cancer therapy,  
also have displayed radiosensitizing eﬀects in many 
preclinical studies and clinical trials [51].
ATM as a Target for Radiosensitization
　 As described above,  molecules involved in DNA 
repair or cell cycle checkpoints can be targets to 
enhance tumor radiosensitivity.  Interest in molecu-
larly targeted therapy has deepened our understanding 
of the signaling pathways for DNA repair and cell 
cycle checkpoints,  and ATM has been revealed to play 
a central in these signaling pathways.  Studies origi-
nally identiﬁed the ATM gene in A-T,  a disease that 
causes several severe disabilities,  such as cerebellar 
degeneration,  immunodeﬁciency,  hypersensitivity to 
radiation and genomic instability,  and increased inci-
dence of malignancies [52,  53].  All patients with A-T 
have mutations in the ATM gene,  and intensive inves-
tigation of such patients and A-T cells has contributed 
to the elucidation of ATM function.  The construction 
of the ATM protein is similar to that of ATM- and 
RAD3-related (ATR),  the DNA-dependent protein 
kinase,  catalytic subunit,  and mammalian target of 
rapamycin (mTOR),  and ATM belongs to the phos-
phatidylinositol 3-kinase (PI3K)-related kinase family.
　 Following DNA damage,  ATM immediately acti-
vates signaling pathways for DNA repair and cell 
cycle checkpoints.  Although recent studies have shown 
that downstream signaling of ATM is becoming 
increasingly complicated,  p53 and Chk2 are undoubt-
edly the main targets of ATM and control the G1/S 
and G2/M checkpoints while interacting with each 
other.  Also,  inhibition of these checkpoints allows 
damaged cells to move to the mitotic phase without 
undergoing proper DNA repair,  leading to mitotic 
catastrophe,  which is currently considered a main 
cause of cell death induced by radiotherapy [54-56].  
Moreover,  ATM is known to aﬀect HR repair by 
directly or indirectly phosphorylating at least 12 tar-
gets,  such as BRCA1/2 and NBS1,  and defects in 
ATM function lead to dysfunction in HR repair [57,  
58].  These ﬁndings indicate that targeted ATM inhi-
bition is an attractive approach to enhancing tumor 
radiosensitivity.
　 Caﬀeine and wortmannin,  which are nonspeciﬁc 
PI3K inhibitors,  have been widely used in studies 
related to ATM/ATR functions [59,  60].  However,  
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some of the eﬀects of caﬀeine and wortmannin in cells,  
such as apoptosis and checkpoint abrogation,  are 
caused not only by ATM/ATR inhibition but also by 
other factors in the PI3K family [60,  61].  Recently,  
researchers developed several more speciﬁc ATM and 
ATM/ATR inhibitors―KU-55933,  CGK733,  and 
CP466722―and tested their potential as radiosensi-
tizers in preclinical studies.  KU-55933 was found to 
exhibit a speciﬁc inhibitory eﬀect on ATM but not on 
other PI3K-family proteins,  such as PI3K,  DNA-PK,  
ATR,  and mTOR,  and sensitized cells to ionizing 
radiation by blocking phosphorylation of γH2AX,  
NBS1,  and Chk1 [62].  CGK733 demonstrated selec-
tive inhibition of ATM and ATR,  which led to block-
age of the checkpoint signaling pathways,  and 
researchers showed that its inhibitory eﬀects were 
more beneﬁcial than its small interfering RNA-
mediated inhibition [63].  CP466722 exhibited inhibi-
tion of ATM and its downstream signaling pathways in 
the same way that KU-55933 did,  and investigators 
emphasized that transient (4h or less) inhibition of 
ATM expression was suﬃcient to increase the radio-
sensitivity of tumor cells [64].  Small interfering 
RNAs and antisense DNA for ATM also exhibited 
potent radiosensitizing eﬀects [65,  66].  Based on 
this preclinical evidence,  ATM inhibitors are expected 
to be promising candidate radiosensitizers.
The MRN Complex as a Target for 
Radiosensitization
　 Although the importance of the ATM signaling 
pathway in DNA repair and cell cycle checkpoints has 
been established,  the MRN complex has emerged as 
an essential factor in ATM activation.  Mre11 and 
Rad50 were originally isolated from the yeast Saccha-
romyces cerevisiae in genetic screens in which an Mre11 
mutant was defective in meiotic recombination [67] 
and a Rad50 mutant was sensitive to DNA damage 
[68].  NBS1 was isolated as a member of the complex 
that binds with Mre11 and Rad50,  and mutations in 
this gene cause NBS,  which is characterized by high 
cancer incidence,  cell-cycle-checkpoint defects,  and 
radiosensitivity [69].  Mutations in the Mre11 gene 
have been reported to cause A-T like disorder [70],  
and deﬁciency of the Rad50 gene causes NBS-like 
disorder [71].  The indispensability of the MRN 
complex to cells is emphasized by the fact that null 
mutations of either of these genes cause embryonic 
lethality in mice [72].  The Mre11 protein is uni-
formly distributed in the nucleus under undamaged 
conditions,  but it migrates to sites of damage within 
30 minutes after DNA DSB induction and forms a 
complex with Rad50 and NBS1,  which is visualized as 
nuclear foci [73].
　 The MRN complex plays important roles in signal 
transduction related to DNA repair and cell cycle 
checkpoints [10].  One of these roles is activation of 
the ATM/ATR signaling pathway.  Dysfunction of the 
MRN complex results in impairment of the ATM sig-
naling pathway,  which leads to hypersensitivity to 
DNA-damaging agents.  The MRN complex has also 
been reported to contribute to the DNA DSB-repair 
pathway directly or indirectly via ATM activation 
[9].  In the HR repair process,  the MRN complex 
serves as a primary damage sensor and is involved in 
the early steps of HR repair,  which include processing 
of the broken DNA ends: in other words,  removal of 
the 5ʼ strand to uncover the 3ʼ single strand [74].  
Whereas Ku70/80 and DNA-PK are well known to be 
the main components in NHEJ,  the importance of the 
MRN complex to NHEJ has only recently been demon-
strated,  and whether the MRN complex is correlated 
with Ku70/80 and DNA-PK in NHEJ remains unclear 
[10,  75].
　 As might be expected from the fact that mutations 
in members of the MRN complex are hypersensitive to 
DNA DSBs,  inhibitors of the MRN complex enhance 
the cytotoxic activity of ionizing radiation.  Although 
disruptions of the MRN complex by gene therapy have 
been reported to be eﬀective in combination with 
radiotherapy,  researchers recently isolated a novel 
small-molecule inhibitor of the MRN complex called 
mirin from a chemical genetic screen [76,  77].  Mirin 
inhibited MRN complex-dependent ATM activation and 
Mre11-associated exonuclease activity,  leading to 
abolishment of the G2/M checkpoint and impairment 
of HR repair.  These results are consistent with the 
known and anticipated functions of the MRN complex.  
Considering the importance of the MRN complex in 
DNA repair and cell cycle checkpoints,  MRN complex 
inhibitors appear to be very promising as radiosensi-
tizers.
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The Radiosensitizing Eﬀect of the Adenoviral 
E1B55kDa Protein
　 We recently demonstrated that telomelysin sensi-
tizes cancer cells to the cytotoxic activity of ionizing 
radiation [78].  Telomelysin is a telomerase-depen-
dent oncolytic adenoviral agent whose replication is 
controlled by the human telomerase reverse tran-
scriptase (hTERT) promoter.  Telomelysin can thus 
induce cell death via oncolysis by replicating only in 
cancer cells whose hTERT activity is high [79-81].  
An American Phase I clinical trial of single-agent 
telomelysin evaluated the clinical safety and pharma-
cokinetics of the agent in the human body following its 
approval by the U.S.  Food and Drug Administration 
in 2006.  When injected intratumorally in patients 
with various solid tumors such as melanoma,  sarcoma,  
lung cancer,  breast cancer,  and head and neck cancer,  
telomelysin proved to be eﬀective and well-tolerated 
without any severe adverse events [82].
　 The adenoviral E1B55kDa protein has been 
reported to play an important role in creating the 
optimal intracellular environment for adenoviral pro-
tein synthesis by inhibiting the function of the MRN 
complex and p53 in cooperation with the adenoviral E4 
protein [83].  Inhibition of the MRN complex is also 
considered to be a self-defense response to concate-
mer formation of the double-strand DNA genome of 
adenovirus by the MRN complex [84-86].  We showed 
that expression of the MRN complex in cancer cells 
began to decrease about 24 h after telomelysin treat-
ment,  when the E1B55kDa protein began to be 
expressed,  which led to inhibition of ATM phospho-
rylation by ionizing radiation and inhibition of DNA 
repair.  We determined the importance of the presence 
of E1B55kDa in regard to this inhibitory eﬀect by 
comparing telomelysin with the E1B-defective onco-
lytic adenovirus dl1520 (onyx-015),  which has been 
used in many clinical trials [87].
　 We demonstrated that inhibition of the MRN com-
plex by telomelysin via the E1B55kDa protein pro-
duced a profound radiosensitizing eﬀect in vitro;  
interestingly,  on the other hand,  ionizing radiation 
increased the cytotoxic activity of telomelysin,  pre-
sumably by increasing viral uptake into cancer cells,  
which means that telomelysin and ionizing radiation 
potentiate each other.  Furthermore,  combined ther-
apy with telomelysin and ionizing radiation exhibited a 
strong synergistic antitumor eﬀect in animal studies 
[78].  A clinical study of the combination of telom-
elysin and ionizing radiation against cancers of the 
head and neck and esophagus is currently under con-
sideration in Japan,  and additional telomelysin-based 
treatment is expected to contribute to improvement of 
the survival rates and quality of life in patients with 
these cancers.  Moreover,  this inhibitory eﬀect on the 
MRN complex via the E1B55kDa protein may apply to 
not only telomelysin but also all of the other oncolytic 
adenoviruses that produce this protein,  which may 
provide new clues to clinical applications of oncolytic 
adenovirotherapy (Fig.  2).
Perspectives on ATM and MRN Complex 
Inhibitors
　 Precise cellular responses to DNA DSBs require 
eﬃcient recognition of the damaged DNA sites and 
organized activation of the signaling pathways leading 
to DNA repair and cell cycle checkpoints.  Numerous 
preclinical studies have shown that ATM and the MRN 
complex play critical roles in this response,  which 
indicates that these molecules are promising targets 
for radiosensitization.  In fact,  the ATM and MRN 
complex inhibitors described above have exhibited 
profound radiosensitizing eﬀects in preclinical studies.  
The next step should be to test these inhibitors toward 
clinical application is to be tested in clinical settings,  
but to our knowledge,  none of them have entered 
clinical trials.
　 One of the factors that could impede the success of 
ATM and MRN complex inhibitors in clinical trials is 
tumor selectivity.  The expression and functions of 
ATM and the MRN complex do not appear to diﬀer 
much in cancer cells and normal cells,  which means 
that unless these inhibitors are delivered to tumors 
selectively,  severe adverse events may occur when 
they are combined with radiotherapy.  Recent develop-
ments in the ﬁeld of drug delivery could have remark-
able outcomes when combined with developments in the 
ﬁeld of drug discovery.  For example,  nanomedicine 
has revolutionized drug delivery,  and nanosized carri-
ers such as liposomes,  polymers,  and micelles increase 
the stability of therapeutic drugs in the bloodstream 
[88].  Moreover,  these carriers can acquire tumor-
targeting potential by being equipped with antibodies 
or peptides that target biomarkers that are overex-
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pressed in tumors [89].  This type of improvement in 
drug delivery may be necessary for the use of ATM or 
MRN complex inhibitors before they enter clinical 
trials.
　 Regarding tumor-targeting potential,  telomelysin 
may be a step ahead of these ATM or MRN complex 
inhibitors because its eﬀect is strictly limited to can-
cer cells with high telomerase activity levels.  Moreover,  
Phase I clinical trials in the United States have 
already determined the safety of monotherapy with 
telomelysin,  and this agent is about to undergo testing 
in combination with ionizing radiation in a clinical trial 
in Japan.
　 However,  telomelysin also has some challenging 
drawbacks that must be overcome in order to increase 
its attractiveness and its application as a cancer 
therapeutic agent.  One of these issues is that telom-
elysin currently can only be administered via local 
injection and not systemically.  The majority of intra-
venously administered adenoviruses become trapped in 
the liver,  and thus they are not present at suﬃcient 
levels at the tumor sites [90].  In addition,  most 
people have neutralizing antibodies against adenovirus 
type 5,  which is one of the common cold viruses.  
Therefore,  telomelysin,  which consists of this adeno-
virus,  is removed by the immune system immediately 
after systemic administration.  For this reason,  appli-
cation of telomelysin is currently limited to cancers 
conﬁned within locoregional areas,  and improvements 
in telomelysin that would facilitate its systemic deliv-
ery will be needed before the drug can be used in the 
treatment of distant metastases.
　 In summary,  the ﬁeld of targeted radiosensitiza-
tion of tumors is developing rapidly and drawing much 
attention.  ATM and the MRN complex play central 
roles in the DNA DSB-response pathways,  and 
inhibitors of these molecules are promising candidate 
radiosensitizing agents.  An upcoming clinical trial of 
telomelysin combined with ionizing radiation will test 
this agentʼs function as an MRN complex inhibitor,  
and the outcome of this trial is expected to open new 
opportunities for other oncolytic adenoviruses that 
produce the E1B55kDa protein as promising radiosen-
sitizers.
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